Kuros Biosciences AG
Kuros Biosciences AG (CSBTF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
csbtf · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Kuros Biosciences AG (CSBTF) measures how much investors pay for each dollar of the company's trailing earnings. CSBTF's current PE ratio of 471.17x is calculated by dividing its stock price of $26.00 by its TTM earnings per share of $0.04. +68.2% elevated vs 5Y avg 280.1x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Kuros Biosciences AGYou CSBTF | $1.0B | 471.17x | +929.2% | $0.04 |
 Ascletis Pharma Inc. ASCLF | $1.4B | N/A | — | -$0.36 |
 China Traditional Chinese Medicine Holdings Co. Limited CHIZF | $1.4B | N/A | — | -$0.07 |
 CStone Pharmaceuticals CSPHF | $1.1B | N/A | — | -$0.31 |
 Mesoblast Limited MEOBF | $2.0B | N/A | — | -$0.08 |
 Nippon Shinyaku Co., Ltd. NPPNY | $1.8B | 10.04x | -78.1% | $116.97 |
 Neuren Pharmaceuticals Limited NURPF | $1.2B | 81.52x | +78.1% | $0.24 |
Industry Average 2 peers with valid PE | — | 45.78x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 551.48x | $0.06 | — | |
2024-12-31 FY2024 | — | $-0.10 | — | |
2023-12-31 FY2023 | — | $-0.38 | — | |
2022-12-31 FY2022 | — | $-0.43 | — | |
2021-12-31 FY2021 | — | $-0.23 | — | |
2020-12-31 FY2020 | — | $-0.47 | — | |
2019-12-31 FY2019 | — | $-0.66 | — | |
2018-12-31 FY2018 | — | $-1.14 | — | |
2017-12-31 FY2017 | — | $-1.88 | — | |
2016-12-31 FY2016 | — | $-3.19 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Kuros Biosciences AG (CSBTF) measures how much investors pay for each dollar of the company's trailing earnings. CSBTF's current PE ratio of 471.17x is calculated by dividing its stock price of $26.00 by its TTM earnings per share of $0.04.
Frequently asked questions
CSBTF pe ratio · 6 questionsCSBTF's current PE ratio is 471.17x as of 2026-06-09, based on a stock price of $26.00 and TTM EPS of $0.04. Data sourced from Financial Modeling Prep via CSBTF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Kuros Biosciences AG SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09